Collectively, our data clearly demonstrate the importance for EZH2 catalytic function to govern expression/action of MR-TFs that drive phenotypic plasticity and cell state transitions allowing prostate adenocarcinoma evolution to NEPC to evade AR signaling inhibitors. This evidence concerns the gene EZH2 and prostate adenocarcinoma.